SCHEMBL188900

SCHEMBL188900

COc1nccc(Br)c1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CCR4 P51679 3/20 0.35
CSNK2A1 P68400 1/20 0.35
HIPK2 Q9H2X6 1/20 0.35
MAPK1 P28482 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PDCD1 Q15116 3/20 0.33
CD274 Q9NZQ7 3/20 0.33
APLNR P35414 1/20 0.33
CCR1 P32246 1/20 0.33
CCR5 P51681 1/20 0.33
CCR8 P51685 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
NFE2L2 Q16236 1/20 0.33
AURKA O14965 1/20 0.33
TTK P33981 1/20 0.33
AURKB Q96GD4 1/20 0.33
INCENP Q9NQS7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26921487 0.89 GPBAR1 (0.33) HPGDSMN1; SMN2CCR4CSNK2A1HIPK2
SCHEMBL18328238 0.79 NFE2L2 (0.36) CCR4MAPK1L3MBTL1PDCD1CD274
SCHEMBL911419 0.78 CCR4 (0.43) CCR4MAPK1L3MBTL1APLNRCCR1
SCHEMBL3475483 0.78 HPGD (0.42) HPGDSMN1; SMN2CSNK2A1HIPK2L3MBTL1
SCHEMBL28634741 0.78 NFE2L2 (0.35) CCR4MAPK1L3MBTL1PDCD1CD274
SCHEMBL22034054 0.77 HPGD (0.37) HPGDSMN1; SMN2CSNK2A1HIPK2APLNR
SCHEMBL27849554 0.77 MAPK1 (0.45) HPGDSMN1; SMN2CCR4MAPK1L3MBTL1
SCHEMBL5942324 0.77 DRD1 (0.39) CCR4MAPK1L3MBTL1APLNRCCR1
SCHEMBL18686677 0.77 SMN1; SMN2 (0.37) HPGDSMN1; SMN2CSNK2A1HIPK2L3MBTL1
SCHEMBL1899766 0.77 NQO2 (0.38) HPGDSMN1; SMN2CSNK2A1HIPK2APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688751-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS Enanta Pharmaceuticals, Inc. (US) 2026-02-11 EP disclosed
WO-2024211658-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. (US) 2024-10-10 WO disclosed
US-20240109900-A1 AZABICYCLIC SHP2 INHIBITORS PROMIDIS S.R.L. (IT) 2024-04-04 US disclosed
EP-4288431-A1 AZABICYCLIC SHP2 INHIBITORS IRBM S.P.A. (IT) 2023-12-13 EP disclosed
CN-116490503-A Casein kinase 1 delta modulators 詹森药业有限公司 2023-07-25 CN disclosed
US-20220289753-A1 SHP2 INHIBITORS IRBM S.P.A. (IT) 2022-09-15 US disclosed
WO-2022167682-A1 AZABICYCLIC SHP2 INHIBITORS IRBM S.P.A. (IT) 2022-08-11 WO disclosed
WO-2020228756-A1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2020-11-19 WO disclosed
EP-3601256-A1 IP6K INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2020-02-05 EP disclosed
WO-2018182051-A1 IP6K INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-10-04 WO disclosed
EP-2401273-A1 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2012-01-04 EP disclosed
EP-2398810-A1 TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE Vertex Pharmaceuticals Incorporated (US) 2011-12-28 EP disclosed
WO-2010135014-A1 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-25 WO disclosed
WO-2010096389-A1 TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109900-A1 AZABICYCLIC SHP2 INHIBITORS PTPN22, PTPN2, PTPN5 HPGD 3717/4885SMN1; SMN2 4426/4885CCR4 1705/4885
US-20220289753-A1 SHP2 INHIBITORS PTPN1, PTPN2, PTPN7 HPGD 4105/4885SMN1; SMN2 4332/4885CCR4 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.